The presence of soluble tumor necrosis factor (TNF) binding proteins (BP) was investigated in the sera of healthy volunteer blood donors and cancer patients. Two distinct types of TNFBP, types A and B, which are immunologically related to the cellular 75-kD TNF receptor (TNFR) and the cellular 55-kD TNFR, respectively, were assessed by immunoassays using nonblocking anti-receptor antibodies and "25I-recombinant human TNFa. As compared to the titers observed in 25 healthy controls, TNFBP types A and B titers were found to be elevated in almost all sera obtained from patients with underlying malignant disease. The highest amounts of TNFBP were seen in the sera of patients with B cell malignancies including hairy cell leukemia (HCL) and type B chronic lymphocytic leukemia. Treatment of HCL patients with recombinant human interferon-a was associated with decrease ofcirculating TNFBP. (J.
Introduction
Tumor necrosis factor (TNF)1 is a pleiotropic cytokine that plays a major role in inflammation and host defense to infection (1, 2) . It exerts antitumor activity in vivo as demonstrated in certain transplanted mouse tumor models (for reviews, see references 1 and 3) . In the context ofother factors present, TNF acts as an antileukemic agent (4) or stimulates leukemia growth in patients with hairy cell leukemia (HCL), type B chronic lymphocytic leukemia (B-CLL) (5-7), and acute myelogenous leukemia (8-10). Recently, two distinct types of cellular TNF receptors (TNFR) have been identified by molecular cloning (11) (12) (13) and have been shown to be differentially expressed on various human cells (14) . Non-cross-reactive monoclonal antibodies (MAb) have been prepared against both the 75-kD type A TNFR (utr MAb series) and the 55-kD type B TNFR (htr MAb series) (14) , and it has been demonstrated that both types of TNFR share a high degree of amino acid sequence homology which is, however, restricted to the extracellular domain ofthe molecules (15) . Human urine and serum contain a TNF inhibitory activity. Molecular cloning identified this molecule as soluble fragments of both TNFR (16, 17) . In the following we refer to these soluble fragments of TNFR as TNF binding proteins (TNFBP) types A and B. In this article, we describe a sensitive assay to detect TNFBP in human serum collected from healthy subjects and patients with a variety of mostly hematopoietic malignancies. Circulating TNFBP levels were found increased in almost all patients' sera as compared to normal controls. Patients with HCL and B-CLL disclosed the highest TNFBP serum levels, particularly of the type A, that decreased during effective recombinant human interferon-a (rhIFNa) therapy.
Methods
Patients. We studied sera from 167 patients with malignant disorders including hematopoietic neoplasias (n = 137) and other tumor types (n = 30). Sera from 25 healthy age-matched subjects served as controls. In selected experiments, sera collected from patients with HCL were also studied during therapy with rhIFNa. All healthy controls and patients investigated were free of concomitant illness, particularly infectious disease. Informed consent was obtained in accordance with our institutional policy.
Serum samples. Blood obtained by venipuncture was allowed to clot at room temperature for 1 h; after centrifugation the serum was stored in volumes of -0.5 ml at -70°C until used.
Antibodies. MAb raised against partially purified TNFR from HL60 cells (htr series) and U937 cells (utr series) were previously described (14) . MAb htr-20 specifically binds to the p55 TNFR (type B) without inhibiting TNF binding (M. Brockhaus, unpublished data). Similarly, utr-4 is a noninhibitory antibody against the p75 TNFR (type A) (14) .
TNFR assay. Sera were diluted 1:20 with a 1% solution of fat-free milk powder in 50 mM Tris-HCI, pH 7.4, 5 mM sodium EDTA, 140 mM sodium chloride, and 0.02% sodium azide (blocking buffer). 96-well polyvinyl microtiter plates (Dynatech Laboratories, Inc., Alexandria, VA) were sensitized with affinity-purified rabbit anti-mouse immunoglobulin (10 lAg/ml) followed by overnight incubation with spent culture medium from the hybridomas htr-20 or utr-4.
The wells were washed once with PBS and incubated for 3 h at 4°C with the diluted serum samples. After three washings with PBS the wells were incubated with radioiodinated rhTNFa (50 gl, 7 X IO' cpm/ ml, sp act 450 Ci/mM) in blocking buffer for 2 h at 4VC. The wells were washed four times with PBS and bound 1251-rhTNFa was determined by gamma scintillation counting.
The TNFBP concentration was expressed as picomole per liter '25I1 rhTNFa binding capacity in serum. The background was not subtracted. Unspecific binding of 1251-rhTNFa in the presence ofan excess of unlabeled competitor TNFa was < 40 pM. The assays were linear for TNFBP in the reported range (not shown). The addition of exogenous rhTNFa (10 ng/ml) to the serum decreased the measured TNFBP concentration by 30% also in the samples with elevated TNFBP (data not shown).
Data analysis. Data are expressed as mean±SE if not otherwise indicated. Data analysis was performed with Tukey's studendized oneway analysis of variance with simultaneous comparisons ofgroups and 5% was chosen as level of significance.
Results TNFBP in serum. Soluble TNFBP of both types A and B were detected at low concentrations (79±14 and 61±12 pM, respectively) in the sera of healthy individuals (Fig. 1 ). From these data a 100 pM TNF binding capacity was considered as the upper normal limit for both TNFBP. Under the assumption of a 1 :1 molar stoichiometry ofthe TNF/TNFBP complex and an average molecular mass of 30 kD for TNFBP, this cutoff is equivalent to a TNFBP concentration of 3 ng/ml. Almost all Decrease ofTNFBP during rhIFNa therapy. We also determined both forms of TNFBP in serum of six HCL patients during treatment with rhIFNa. The serum levels of both TNFBP began to decrease several weeks after initiation of rhIFNa therapy (Fig. 2) , and the decrease was most pronounced in patients presenting with very high type A TNFBP concentrations before treatment. At the time of TNFBP measurement during rhIFNa therapy the patients were all in complete (patients 2, 4, and 6) or partial (patients 1, 3, and 5) remission.
TNFBP type A decreased in all patients during therapy between 276 and 2,890 pM. In two patients with untreated stable 9 10 Figure 1 . platelets > 100,000/,gl, neutrophils > 1,500/,Ml), whereas patients 1, 3, and 5 were in partial remission (> 5% hairy cells in the bone marrow core biopsy but at least a 50% decrease from baseline, and improvement in peripheral counts) after rhIFNa treatment.
disease no similar reduction was found. The serum concentration ofTNFBP remained constant at a low level for an observation period of 72 wk (data not shown).
Discussion
We have analyzed the sera of 167 patients with both hematologic and nonhematologic malignancies for the presence of TNFBP. A sandwich type ofimmunoassays using immobilized anti-TNFR MAb and '25I-rhTNFa allowed us to specifically determine types A and B TNFBP that are antigenically equivalent to the 75-kD TNFR (MAb utr-4) and the 55-kD TNFR (MAb htr-20), respectively. A significant increase of the mean TNFBP serum concentration was detected in all patient groups, but the most notable result was the exceptionally high TNFBP concentrations with predominance oftype A over type B TNFBP in the sera of most HCL and B-CLL patients. In experimental edotoxinemia in healthy subjects only a maximal fivefold increase of both types A and B TNFBP levels were observed (20) . The cellular source of TNFBP in HCL and B-CLL is presently unknown. However, we observed that levels of TNFBP decreased in HCL during effective rhIFNa therapy, suggesting a correlation of circulating TNFBP with tumor cell load. However, TNFBP serum concentrations were not correlated with clinical staging of HCL and B-CLL (18, 19) . TNF has been found to be produced by HCL and B-CLL cells (5, 7, 21) and to stimulate proliferation of HCL and B-CLL cells in vitro (5, 6) . It is possible that TNF serves as an autocrine growth factor in both disease states and thus TNFBP may play an important role in the regulation of neoplastic cell growth in HCL and B-CLL. It is of note, however, that more mature B-cell malignancies such as multiple myeloma failed to exhibit increased type A TNFBP levels.
In most other malignancies elevated serum concentrations of predominantly type B TNFBP with a fairly constant ratio of type B to type A proteins were disclosed. Therefore we assume that the TNFBP in these cases are not produced by the neoplastic cells themselves. It has, for instance, been shown that neutrophiles are a potent source of TNFBP when activated (22). The existence of circulating soluble forms of cytokine receptor proteins applies for a variety ofother cytokine receptors as well. In contrast, however, to the soluble IL-2, IL-4, or IL-7 receptors (23, 24) , soluble TNFR are most likely the products of posttranslational processing of the TNFR molecules (1 1,
15-17).
Once in systemic circulation, soluble receptor protein fragments such as TNFBP can compete with cell-bound receptors for ligand. They may thus form a pool of scavenger molecules which neutralize highly toxic cytokines such as TNF. More complex functions for soluble receptor fragments are conceivable, if, e.g., the existence of membrane-bound TNF is taken into account. From a practical point of view, combined measurements of TNF and inhibiting TNFBP, rather than that of TNF alone, will provide an additional important parameter of the cytokine status in a given clinical situation.
